On February 18, 2021, Regor Therapeutics, a clinical-stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders, and metabolic diseases, announced the completion of a $90 million Series B financing. The financing was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital, and Vertex Ventures China. Wilson Sonsini Goodrich & Rosati advised Lilly Asia Ventures on IP matters related to the transaction.

Regor Therapeutics was founded in 2018 by a group of veteran drug hunters with extensive research and leadership experience at top multinational pharmaceutical companies. It is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally. By leveraging computer accelerated rational discovery (CARD), a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion.

The Wilson Sonsini team that advised Lilly Asia Ventures on the financing included Senior Of Counsel Karen Wong, Of Counsel Richard Wang, patent agent Brandon Tavshanjian, and IP specialist Quinn Yu.

For more information, please see Regor Therapeutics’ press release.